Metastatic Gastric Cancer: Synergizing and Sequencing Targeted Therapy with First-Line Immunotherapy

This publication has 29 references indexed in Scilit:

• Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer
  JAMA, 2023
• SPOTlight on GLOW
  Cell Reports Medicine, 2023
• Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer
  ESMO Open, 2023
• Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer
  JAMA Oncology, 2022
• Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial
  Gastric Cancer, 2022
• Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial
  Gastric Cancer, 2021
• Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer
  JAMA Oncology, 2020
• Efficacy of immune‐checkpoint inhibitors in metastatic gastric or gastroesophageal junction adenocarcinoma by patient subgroups: A systematic review and meta‐analysis
  Cancer Medicine, 2020
• Outlooks on Epstein-Barr virus associated gastric cancer
  Cancer Treatment Reviews, 2018
• Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
  JAMA Oncology, 2018